Topical treatments for chronic plaque psoriasis of the scalp: A systematic review

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 519-527

  Mason, A R ^a   Mason, J M ^b   Cork, M J ^c   Hancock, H ^b   Dooley, G ^d  

^a UNIVERSITY OF YORK   (United Kingdom)

^b DURHAM UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d Metaxis Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMCINONIDE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CICLOPIROXOLAMINE; CLOBETASOL PROPIONATE; COAL TAR; COLECALCIFEROL DERIVATIVE; DEXAMETHASONE 17,21 DIPROPIONATE; FLUOCINOLONE ACETONIDE; HALCINONIDE; PLACEBO; SALICYLIC ACID; VITAMIN D DERIVATIVE;

ARTICLE; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCALP; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; CHOLECALCIFEROL; CHRONIC DISEASE; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCALP DERMATOSES;

EID: 84883414352     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12393     Document Type: Article

References (59)

1. Hellgren L. Psoriasis,. The Prevalence in Sex, Age and Occupational Groups in Total Populations in Sweden: Morphology, Inheritance and Association with other Skin and Rheumatic Diseases. Stockholm: Almqvist & Wiksell, 1967.
2. Krueger GG, Bergstresser PR, Lowe NJ, et al,. Psoriasis. J Am Acad Dermatol 1984; 11 (5 Pt 2): 937-47.
3. Simons RD,. Additional studies on psoriasis in the tropics and in starvation camps. J Invest Dermatol 1949; 12: 285-94.
4. Yip SY,. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 1984; 10: 965-8.
5. Griffiths CEM, Christophers E, Barker JNWN, et al,. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258-62.
6. van de Kerkhof PCM,. Combinations and comparisons. Clin Dermatol 1997; 15: 831-4.
7. Gupta MA, Gupta AK, Watteel GN,. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis 1998; 61: 339-42.
8. Finlay AY,. Coping with psoriasis. Br Med J 1995; 310: 1673.
9. Finlay AY,. Psoriasis from the patient's point of view. Arch Dermatol 2001; 137: 352-3.
10. Finlay AY, Coles EC,. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-44.
11. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
12. McKenna SP, Cook SA, Whalley D, et al,. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 2003; 149: 323-31.
13. Ortonne JP,. Psoriasis: evaluation of quality of life. Ann Dermatol Venereol 2000; 127 (Suppl. 2): 2s19-22.
14. Richards HL, Fortune DG, Main CJ, Griffiths CE,. Stigmatization and psoriasis. Br J Dermatol 2003; 149: 209-11.
15. Stern RS,. Epidemiology of psoriasis. Dermatol Clin 1995; 13: 717-22.
16. Chan CS, Van Voorhees AS, Lebwohl MG, et al,. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60: 962-71.
17. Tagami H,. Triggering factors. Clin Dermatol 1997; 15: 677-85.
18. Barker JN,. The pathophysiology of psoriasis. Lancet 1991; 338: 227-30.
19. Griffiths CEM,. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol 2003; 17 (Suppl. s2): 1-5.
20. Stern RS,. Psoriasis. Lancet 1997; 350: 349-53.
21. Griffiths CEM, Barker JNWN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
22. Tsoi LC, Spain SL, Knight J, et al,. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012; 44: 1341-8.
23. Papp K, Berth-Jones J, Kragballe K, et al,. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol 2007; 21: 1151-60.
24. Bottomley JM, Taylor RS, Ryttov J,. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence. Curr Med Res Opin 2011; 27: 251-68.
25. American Academy of Dermatology Work Group;, Menter A, Korman NJ, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137-74.
26. Mason AR, Mason J, Cork M, et al,. Topical treatments for chronic plaque psoriasis (protocol). Cochrane Database Syst Rev 2004; 1: CD005028.
27. Mason AR, Mason J, Cork M, et al,. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009; 2: CD005028.
28. Mason AR, Mason J, Cork M, et al,. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013; 3: CD005028.
29. van de Kerkhof PCM,. An update on vitamin D3 analogues in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 1998; 11: 2-10.
30. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011. (last accessed 29 July 2013).
31. Barrett C, Lowson D, Blades KJ,; MCS 9506 INT investigators. Limited benefit of combined use of tar-based shampoo with 50 microg/ml calcipotriol solution in scalp psoriasis. J Dermatolog Treat 2005; 16: 175.
32. Buckley C, Hoffmann V, Shapiro J, et al,. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008; 217: 107-13.
33. Cook-Bolden FE, Goffe BS, Hudson CP, Sofen HL,. Efficacy and safety results from a randomized, double-blind, vehicle-controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp. J Am Acad Dermatol 2010; 62 (3 Suppl. 1): AB140.
34. Duweb GA, Abuzariba O, Rahim M, et al,. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 2000; 20: 65-8.
35. Elie R, Durocher LP, Kavalec EC,. Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J Int Med Res 1983; 11: 108-12.
36. Ellis CN, Horwitz SN, Menter A,. Amcinonide lotion 0·1% in the treatment of patients with psoriasis of the scalp. Curr Ther Res Clin Exp 1988; 44: 315-24.
37. Franz TJ, Parsell DA, Halualani RM, et al,. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: 628-32.
38. Franz TJ, Parsell DA, Myers JA, Hannigan JF,. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol 2000; 39: 535-8.
39. Green C, Ganpule M, Harris D, et al,. Comparative effects of calcipotriol (Mc903) solution and placebo (vehicle of Mc903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130: 483-7.
40. Jarratt M, Breneman D, Gottlieb AB, et al,. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004; 3: 367-73.
41. Jemec GBE, Ganslandt C, Ortonne J-P, et al,. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59: 455-63.
42. [No author listed] A randomized, double- blind, parallel group, dose-ranging comparison of the efficacy and safety of calcipotriene solution in the treatment of scalp psoriasis. American Academy of Dermatology, 54th annual meeting; 10-15 February 1996.
43. Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al,. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994; 131: 678-83.
44. Klaber MR, McKinnon C,. Calcipotriol (DovonexR) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (CapasalR) shampoo, and long-term experience. J Dermatolog Treat 2000; 11: 21-8.
45. Köse O,. Calcipotriol ointment vs clobetasol solution in scalp psoriasis. J Dermatolog Treat 1997; 8: 287.
46. Kragballe K, Hoffmann V, Ortonne JP, et al,. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol 2009; 161: 159-66.
47. Lepaw MI,. Double-blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis 1978; 21: 571-3.
48. Luger TA, Cambazard F, Larsen FG, et al,. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008; 217: 321-8.
49. Olsen EA, Cram DL, Ellis CN, et al,. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24: 443-7.
50. Pauporte M, Maibach H, Lowe N, et al,. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatolog Treat 2004; 15: 360-4.
51. Poulin Y, Papp K, Bissonnette R, et al,. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. Cutis 2010; 85: 43-50.
52. Reygagne P, Mrowietz U, Decroix J, et al,. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat 2005; 16: 31-6.
53. Shuttleworth D, Galloway DB, Boorman GC, Donald AE,. A double-blind, placebo-controlled study of the clinical efficacy of ciclopirox olamine (1.5%) shampoo for the control of scalp psoriasis. J Dermatolog Treat 1998; 9: 163-7.
54. Tyring S, Mendoza N, Appell M, et al,. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol 2010; 49: 1328-33.
55. van de Kerkhof PCM, Green C, Hamberg KJ, et al,. Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 2002; 204: 214-21.
56. van de Kerkhof PCM, Hoffmann V, Anstey A, et al,. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009; 160: 170-6.
57. Luger T, Kidson P, Cambazard F, Larsen FG,. A 1-year, randomized, double-blind safety study of long-term treatment of a new gel formulation containing calcipotriene plus betamethasone dipropionate in scalp psoriasis. J Am Acad Dermatol 2008; 58: AB134.
58. Joint Formulary Committee. British National Formulary 64. September 2012. London: Pharmaceutical Press, 2012.
59. Carey W, Glazer S, Gottlieb AB, et al,. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006; 54 (4 Suppl. 1): S171-81.